Cargando…

Rituximab for Refractory Rheumatoid Arthritis: A 24-Week Open-Label Prospective Study

OBJECTIVES: To study the efficacy of rituximab in active rheumatoid arthritis (RA) patients refractory to disease modifying anti-rheumatic drugs (DMARDs) including the tumor necrosis factor (TNF)-α antagonists. METHODS: Adult patients with active RA despite adequate therapies with conventional DMARD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho, Ling Yin, Mok, Chi Chiu, To, Chi Hung, Mak, Anselm, Cheung, Mei Yuk, Yu, Ka Lung
Formato:	Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers Ltd. 2007
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2581826/ https://www.ncbi.nlm.nih.gov/pubmed/19088893 http://dx.doi.org/10.2174/1874312900701010001

Ejemplares similares

Rituximab for the treatment of rheumatoid arthritis: an update
por: Mok, Chi Chiu
Publicado: (2013)

B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients
por: Bruijnen, Stefan, et al.
Publicado: (2016)

Rituximab for Rheumatoid Arthritis
por: Cohen, Marc D., et al.
Publicado: (2015)

A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study
por: Stradner, Martin H., et al.
Publicado: (2016)

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
por: Juge, Pierre-Antoine, et al.
Publicado: (2017)

Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis
por: Bonnet, Isabelle, et al.
Publicado: (2021)

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
por: Delabaye, Isabelle, et al.
Publicado: (2010)

Rituximab and its potential for the treatment of rheumatoid arthritis
por: Bryant, Adam, et al.
Publicado: (2006)

Targeted therapies in rheumatoid arthritis: Focus on rituximab
por: Teng, YKO, et al.
Publicado: (2007)

Rituximab therapy in Greek patients with rheumatoid arthritis
por: Tsiakalos, Aristotelis P, et al.
Publicado: (2008)

Seronegative and seropositive rheumatoid arthritis treated with rituximab
por: Velloso Feijoo, Maria Luisa, et al.
Publicado: (2012)

Update on the use of rituximab for intractable rheumatoid arthritis
por: Looney, R John
Publicado: (2009)

Low-Dose Sirolimus Immunoregulation Therapy in Patients with Active Rheumatoid Arthritis: A 24-Week Follow-Up of the Randomized, Open-Label, Parallel-Controlled Trial
por: Wen, Hong-Yan, et al.
Publicado: (2019)

Repeated B-cell depletion with rituximab in rheumatoid arthritis
por: Edwards, J, et al.
Publicado: (2003)

Rituximab treatment in rheumatoid arthritis: how does it work?
por: Boumans, Maria JH, et al.
Publicado: (2009)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Long-term persistence with rituximab in patients with rheumatoid arthritis
por: Oldroyd, Alexander G S, et al.
Publicado: (2018)

Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis
por: Kilic, Levent, et al.
Publicado: (2018)

Tuberculosis Arthritis in the Wrist While Using Rituximab for Rheumatoid Arthritis Treatment
por: Ulusoy, Hasan, et al.
Publicado: (2020)

Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2017)

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
por: Tuscano, Joseph M, et al.
Publicado: (2009)

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2011)

Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis
por: Lehane, P B, et al.
Publicado: (2014)

Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis
por: Sweeney, Shannon R, et al.
Publicado: (2016)

(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges
por: den Broeder, Alfons A, et al.
Publicado: (2021)

Enteroviral Meningoencephalitis as a Complication of Rituximab Therapy for Rheumatoid Arthritis
por: Cook, Samuel G, et al.
Publicado: (2021)

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis
por: Park, Won, et al.
Publicado: (2017)

Intravenous pamidronate for refractory rheumatoid arthritis
por: Salesi, Mansour, et al.
Publicado: (2012)

Rituximab in refractory myasthenia gravis: a prospective, open‐label study with long‐term follow‐up
por: Anderson, Dustin, et al.
Publicado: (2016)

Prevalence of the Antiphospholipid Syndrome and Its Effect on Survival in 679 Chinese Patients With Systemic Lupus Erythematosus: A Cohort Study
por: Mok, Chi Chiu, et al.
Publicado: (2013)

Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial—an open-label, one-year, prospective study—Interim analysis of 32 patients for 24 weeks
por: Tsuboi, Hiroto, et al.
Publicado: (2015)

Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
por: Hainsworth, John D
Publicado: (2003)

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
por: Mishra, Richa, et al.
Publicado: (2009)

Marked deterioration in rheumatoid arthritis associated bronchiectasis following treatment with Rituximab
por: Musameh, K., et al.
Publicado: (2019)

Low-dose rituximab protocol in rheumatoid arthritis—outcome and economic impact
por: Chandramohan, Parvathypriya, et al.
Publicado: (2021)

Rituximab for steroid-resistant organising pneumonia in a woman with rheumatoid arthritis
por: Loftis, Christine Elizabeth, et al.
Publicado: (2022)

Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology
por: Mok, Chi Chiu, et al.
Publicado: (2010)

Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
por: Cohen, Stanley B., et al.
Publicado: (2018)

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
por: Humby, Frances, et al.
Publicado: (2021)

Single-centre experience of refractory rheumatoid arthritis
por: Fitton, John, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m65onu9hahfll0v39jaj3sgatg